Specialities

Specialities

Alzheimer's Disease and Dementia
Brain Trauma
COVID-19
Epilepsy
Headache Disorders
Neurodegenerative Diseases
Movement Disorders
Multiple Sclerosis
Neuroimmunology
Neurological Oncology
Neurometabolic Disease
Neuromuscular Diseases
Neuropathic Pain
Stroke
Neurosurgery
Paediatric Neurology
Parkinson's Disease
Psychiatric Disorders
Rare Diseases
Sleep Disorders
Central Nervous Disorders
Neuroradiology
Search

Trending Topic

Motor neuron synapses with muscle fiber via electrical impulse transmission and neurotransmitter release, forming neuromuscular junctions , motor neuron, neuroscience
15 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

SOD1-ALS from Gene Discovery to Targeted Therapeutics: A Comprehensive Review

Joshua Newman, Phillipe Corcia, Angela Genge

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of upper and lower motor neurons that results in progressive motor impairment. ALS is the most common disease of motor neurons with an annual incidence of approximately 1.7–2.5 per 100,000 people. It is a terminal condition with a typical life expectancy of 2–5 years from symptom onset. […]

touchREVIEWS in Neurology. 2025;21(1):1–5:Online ahead of journal publication

Connect With Us:

Facebook
X (Twitter)
Instagram
Youtube
Linkedin

Search Results

Showing Results for MOXIe

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
Mark CompleteCompleted
BookmarkBookmarked

Omaveloxolone for the Treatment of Friedreich’s Ataxia

Riley Kessler, Sonal Sharma, David R Lynch

Friedreich’s ataxia (FRDA), a neurodevelopmental and progressive neurodegenerative disease, is the most common inherited form of ataxia, with disease incidence as high as 1 in 29,000 in Caucasian populations.1 Patients typically present with ataxia from ages 7 to 15 years and lose the ...

touchREVIEWS in Neurology. 2023;19(2):10-15
Mark CompleteCompleted
BookmarkBookmarked

Emerging Therapies in Friedreich’s Ataxia: A Review

Susan Perlman

It has been nearly 160 years since Friedreich’s ataxia (FRDA) was clinically recognized and described1 and 25 years since the FXN gene was discovered.2 Despite this, there are still no approved therapies for FRDA. FRDA is an autosomal, recessively inherited, neurodegenerative ...

touchREVIEWS in Neurology. 2022;18(1):32–7 DOI: https://doi.org/10.17925/USN.2022.18.1.32

Latest articles videos and clinical updates - straight to your inbox

Close Popup